Floatz logo

Tas-102

Extensive Stage Lung Small Cell Carcinoma

Taiho Oncology, Inc.unclassifiedPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Extensive Stage Lung Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Iadademstat
Yale University
Phase 2BB
Niraparib
ETOP IBCSG Partners Foundation
Phase 3BB
azd5305
SWOG Cancer Research Network
Phase 2B
Talzenna
University Health Network, Toronto
Phase 2B
Ceralasertib
SWOG Cancer Research Network
Phase 2CCC

View all 15 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →